Hemogenyx Pharmaceuticals
An October 2026 company announcement describes an in vitro feasibility study combining FLT3 CAR mRNA with Nitto’s cell-targeted LNPs. This is an early in vivo CAR-T development effort, not human in vivo treatment. Clinical HG-CT-1 is a separate ex vivo product.
Corporate information
- Company entity
- Hemogenyx Pharmaceuticals
- Headquarters / principal office
- London headquarters; research subsidiaries in New York City ↗
- Founded
- 2013 (UK listed legal entity incorporated) ↗
- Ownership / capital status
- Publicly tradedLondon Stock Exchange-listed (HEMO) ↗
- Official corporate reference
- https://hemogenyx.com/ ↗ ↗
- LinkedIn company page
- Independent company page not verified
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Start with public sources and capability boundaries; company claims are not independent certification.
Ask AI ↗Public evidence snapshot
An October 2026 company announcement describes an in vitro feasibility study combining FLT3 CAR mRNA with Nitto’s cell-targeted LNPs. This is an early in vivo CAR-T development effort, not human in vivo treatment. Clinical HG-CT-1 is a separate ex vivo product.
This profile is a research snapshot, not a company endorsement. Check original sources for current information.
Original sources
- Hemogenyx Pharmaceuticals — primary program / ownership disclosure
- Hemogenyx Pharmaceuticals – Breakthrough therapies for the treatment of blood diseases and viral infections
- Hemogenyx — About
- Founding / incorporation disclosure — scope stated in field